Jeffrey R. Latts

Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.

Berlex, Inc. manufactured pharmaceutical company. It developed novel diagnostics and therapeutics, which address unmet medical needs. It used to researches, develops, manufactures and markets ethical pharmaceuticals in five strategic areas such as female healthcare, diagnostic imaging, dermatology, oncology and therapeutics. The company was headquartered in Wayne, NJ

Virobay, Inc. develops protease inhibitors for the treatment of neuropathic pain, cancer, autoimmune and liver diseases. It utilize cysteine cathepsin platform for the development and commercialization of novel drugs. The firm's research & development activities focuses on neuropathic pain, autoimmune diseases and liver fibrosis. The company was founded by Robert F. G. Booth on May 18, 2006 and is headquartered in Menlo Park, CA.